A study of the safety and immunogenicity of two different recombinant DNA yeast-derived hepatitis B vaccines was conducted in 90 young adults according to a 0-, 1-, and 6-month vaccination schedule. Preliminary results using the 20 μg SmithKline Biologicals or 10 μg Merck Sharp & Dohme recombinant yeast-derived hepatitis B vaccines indicate that both vaccines are clinically safe and immunogenic. Only minor side effects have thus far been reported. Seroconversion rates among vaccine recipients were 80% or greater after the first two injections with either vaccine, and 100% after the third dose of the SmithKline Biologicals recombinant DNA hepatitis B vaccine.
Immunogenicity of yeast-derived hepatitis B vaccines in young adults / F. BERGAMINI, A.R. ZANETTI. - In: POSTGRADUATE MEDICAL JOURNAL. - ISSN 0032-5473. - 63:2(1987), pp. 137-138.
Immunogenicity of yeast-derived hepatitis B vaccines in young adults
F. BERGAMINIPrimo
;A.R. ZANETTIUltimo
1987
Abstract
A study of the safety and immunogenicity of two different recombinant DNA yeast-derived hepatitis B vaccines was conducted in 90 young adults according to a 0-, 1-, and 6-month vaccination schedule. Preliminary results using the 20 μg SmithKline Biologicals or 10 μg Merck Sharp & Dohme recombinant yeast-derived hepatitis B vaccines indicate that both vaccines are clinically safe and immunogenic. Only minor side effects have thus far been reported. Seroconversion rates among vaccine recipients were 80% or greater after the first two injections with either vaccine, and 100% after the third dose of the SmithKline Biologicals recombinant DNA hepatitis B vaccine.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
